Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (391-400 of 627) with videos related to

Pageof 63
Sort By:
Vascular Medicine (London, England)|June 4, 2021
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trialJudith Hsia, Sarah T Kavanagh, Charles W Hopley, et al.
The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation. Cardiovascular Interventions|February 24, 2022
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPIONBenjamin E Peterson, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|June 27, 2015
Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation CohortLarry A Allen, Gregg C Fonarow, DaJuanicia N Simon, et al.
American Heart Journal|September 7, 2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trialRohan Shah, Anne Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|June 19, 2018
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarctionJennifer A Rymer, Michael W Tempelhof, Robert M Clare, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
American Heart Journal|July 29, 2014
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registryBenjamin A Steinberg, Rosalia G Blanco, Donna Ollis, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|May 30, 2026
Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health StudyGracia Fahed, Diona Gjermeni, Nicholas Cauwenberghs, et al.
Pageof 63

Showing results (391-400 of 627) with videos related to

Sort By:
Pageof 63
Vascular Medicine (London, England)|June 4, 2021
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trialJudith Hsia, Sarah T Kavanagh, Charles W Hopley, et al.
The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation. Cardiovascular Interventions|February 24, 2022
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPIONBenjamin E Peterson, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|June 27, 2015
Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation CohortLarry A Allen, Gregg C Fonarow, DaJuanicia N Simon, et al.
American Heart Journal|September 7, 2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trialRohan Shah, Anne Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|June 19, 2018
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarctionJennifer A Rymer, Michael W Tempelhof, Robert M Clare, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
American Heart Journal|July 29, 2014
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registryBenjamin A Steinberg, Rosalia G Blanco, Donna Ollis, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|May 30, 2026
Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health StudyGracia Fahed, Diona Gjermeni, Nicholas Cauwenberghs, et al.
Pageof 63